SCHEMBL15420504

SCHEMBL15420504

Cc1cnn(-c2ccc(OC[C@H]3OCCC[C@@H]3NS(=O)(=O)C3CC3)c(F)c2)c1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.35
KAT5 Q92993 1/20 0.35
KAT6A Q92794 4/20 0.34
RIPK2 O43353 1/20 0.33
PRKCQ Q04759 1/20 0.33
MELK Q14680 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CNR2 P34972 3/20 0.32
SYK P43405 1/20 0.32
RXRA P19793 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2B Q13224 1/20 0.31
ALK Q9UM73 1/20 0.31
TSHR P16473 1/20 0.30
CSF1R P07333 1/20 0.30
MAPT P10636 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21795661 0.92 SCN9A (0.40) SCN9AKAT5KAT6ARIPK2PRKCQ
SCHEMBL15420798 0.92 SCN9A (0.40) SCN9AKAT5KAT6ARIPK2PRKCQ
SCHEMBL15420670 0.91 SCN9A (0.36) SCN9AKAT5KAT6ARIPK2PRKCQ
SCHEMBL21795637 0.91 SCN9A (0.36) SCN9AKAT5KAT6ARIPK2PRKCQ
SCHEMBL15420526 0.90 SCN9A (0.34) SCN9ARIPK2PRKCQMELKL3MBTL1
SCHEMBL15420627 0.86 RAB9A (0.38) KAT5RIPK2MAPTRAB9A
SCHEMBL21795675 0.83 SCN9A (0.38) SCN9ARIPK2PRKCQMELKL3MBTL1
SCHEMBL15420693 0.83 SCN9A (0.38) SCN9ARIPK2PRKCQMELKL3MBTL1
SCHEMBL15420287 0.82 SCN9A (0.35) SCN9AKAT5RIPK2PRKCQMELK
SCHEMBL15419966 0.77 RAB9A (0.39) KAT5RIPK2ALKMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 SCN9A 648/4885KAT5 2329/4885KAT6A 1800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.